Skip to main content

Table 4 5-Azacytidine (5-Aza) as maintenance therapy after haematopoietic transplantation (HSCT)

From: Epigenetic approaches in stem cell transplantation

Author

n

Agent

Disease

Duration

Outcome

Ref.

de Lima 2007

40

5-Aza

AML/MDS

up to 4 cycles at 28 days

11× relapse

(de Lima et al. 2007)

Jabbour 2009

8

5-Aza (+3× HSCT)

7× AML, 1× ALL

median 8 cycles á 28 days (up to 22 cycles)

3 x relapse, 7× alive

(Jabbour et al. 2009)

  1. AML acute myeloid leukaemia, MDS myelodysplasia, ALL acute lymphoblastic leukaemia